102 related articles for article (PubMed ID: 20574622)
1. Skin necrosis revealing antiphospholipid syndrome during immunotherapy for melanoma.
Gressier L; Guilpain P; Gorin I; Carlotti A; Goulvestre C; Boitier F; Guillevin L; Avril MF; Mouthon L; Dupin N
Acta Derm Venereol; 2010 Jul; 90(4):433-4. PubMed ID: 20574622
[No Abstract] [Full Text] [Related]
2. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
[No Abstract] [Full Text] [Related]
3. [To outwit melanoma with its own tricks].
Bischoff A
MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
[No Abstract] [Full Text] [Related]
4. Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C.
Balderramo DC; García O; Colmenero J; Espinosa G; Forns X; Ginès P
Dig Liver Dis; 2009 Jul; 41(7):e4-7. PubMed ID: 18243078
[TBL] [Abstract][Full Text] [Related]
5. Severe hypotension following inadvertent intravenous administration of interferon alfa-2a.
Hanson DS; Leggette CT
Ann Pharmacother; 1997 Mar; 31(3):371-2. PubMed ID: 9066950
[No Abstract] [Full Text] [Related]
6. Widespread cutaneous necrosis as the initial manifestation of the antiphospholipid antibody syndrome.
Abernethy ML; McGuinn JL; Callen JP
J Rheumatol; 1995 Jul; 22(7):1380-3. PubMed ID: 7562777
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
Bajetta E
Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
[No Abstract] [Full Text] [Related]
8. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.
Dummer R; Garbe C; Thompson JA; Eggermont AM; Yoo K; Maier T; Bergstrom B
J Clin Oncol; 2006 Mar; 24(7):1188-94. PubMed ID: 16505439
[TBL] [Abstract][Full Text] [Related]
9. Abducens palsy and Sjogren's syndrome induced by pegylated interferon therapy.
Oishi A; Miyamoto K; Kashii S; Yoshimura N
Br J Ophthalmol; 2007 Jun; 91(6):843-4. PubMed ID: 17510485
[No Abstract] [Full Text] [Related]
10. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha.
Vaishampayan U; Abrams J; Darrah D; Jones V; Mitchell MS
Clin Cancer Res; 2002 Dec; 8(12):3696-701. PubMed ID: 12473578
[TBL] [Abstract][Full Text] [Related]
11. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma.
Lohmann CP; Kroher G; Bogenrieder T; Spiegel D; Preuner J
Lancet; 1999 Apr; 353(9161):1326. PubMed ID: 10218534
[No Abstract] [Full Text] [Related]
12. Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
Recchia F; Candeloro G; Necozione S; Fumagalli L; Bratta M; Rea S
Anticancer Drugs; 2008 Feb; 19(2):201-7. PubMed ID: 18176117
[TBL] [Abstract][Full Text] [Related]
13. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].
Baldueva IA; Novik AV; Moiseenko VM; Nekhaeva TL; Danilova AB; Danilov AO; Protsenko SA; Petrova TIu; Uleĭskaia GI; Shchekina LA; Semenova AI; Mikhaĭlichenko TD; Teletaeva GM; Zhabina AS; Volkov NV; Komarov IuI
Vopr Onkol; 2012; 58(2):212-21. PubMed ID: 22774527
[TBL] [Abstract][Full Text] [Related]
14. The adjuvant treatment of malignant melanoma.
Reintgen D; Kirkwood J
J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
[TBL] [Abstract][Full Text] [Related]
15. Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy.
Hansen BD; Schmidt H; von der Maase H; Sjoegren P; Agger R; Hokland M
Acta Oncol; 2006; 45(4):400-5. PubMed ID: 16760175
[TBL] [Abstract][Full Text] [Related]
16. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma.
Johnson DM; Hayat SQ; Burton GV
J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440
[No Abstract] [Full Text] [Related]
17. Cutaneous necrosis complicating the injection of pegylated interferon alpha-2b in a patient with chronic hepatitis C.
Rosina P; Girolomoni G
Acta Dermatovenerol Croat; 2008; 16(1):35-7. PubMed ID: 18358108
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
19. A levitating tattoo in a hepatitis C patient on treatment.
Atluri D; Iduru S; Veluru C; Mullen K
Liver Int; 2010 Apr; 30(4):583-4. PubMed ID: 20015152
[No Abstract] [Full Text] [Related]
20. [Therapeutic principles in systemic lupus erythematosis with phospholipid syndrome].
Reshetniak TM; Alekberova ZS; Nasonov EL; Nasonova VA
Ter Arkh; 1998; 70(5):83-7. PubMed ID: 9644754
[No Abstract] [Full Text] [Related]
[Next] [New Search]
